schizophrenia

News and resources

Month: March 2026

Mar 31 2026

Would Earlier Initiation of Clozapine Improve First Episode Psychosis Outcomes?

by Clinical Editor

No Comments

Higher response rates with clozapine after a single treatment failure raise questions about current recommendations and whether it should be used earlier in first-episode psychosis.

Mar 31 2026

Why this Stanford psychiatrist thinks diet can influence serious mental health disorders

by Clinical Editor

No Comments

Shebani Sethi is at the vanguard of metabolic psychiatry, a field that investigates the link between diet and serious mental health disorders.

Mar 30 2026

Would Earlier Initiation of Clozapine Improve FEP Outcomes? – Medscape

by Clinical Editor

No Comments

Would Earlier Initiation of Clozapine Improve FEP Outcomes? Medscape

Mar 29 2026

Health Rounds: Researchers find biomarker that could lead to improved schizophrenia treatments – Reuters

by Clinical Editor

No Comments

Health Rounds: Researchers find biomarker that could lead to improved schizophrenia treatments Reuters

Mar 29 2026

The direct and indirect costs of schizophrenia cause a sizable societal burden. – Psychology Today

by Clinical Editor

No Comments

The direct and indirect costs of schizophrenia cause a sizable societal burden. Psychology Today

Mar 29 2026

Phase 2 Trial of LB-102 for Schizophrenia Shows Positive Impact on Cognitive Performance – Psychiatric Times

by Clinical Editor

No Comments

Phase 2 Trial of LB-102 for Schizophrenia Shows Positive Impact on Cognitive Performance Psychiatric Times

Mar 29 2026

Health rounds: Researchers find biomarker that could lead to improved schizophrenia treatments

by Clinical Editor

No Comments

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) March 27 (Reuters) – Researchers have identified a biomarker linked to...

Mar 28 2026

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

by Clinical Editor

No Comments

Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when …

Mar 28 2026

Small RNAs offer new clues to schizophrenia and bipolar disorder

by Clinical Editor

No Comments

For decades, scientists studying brain disorders have focused almost exclusively on proteins and the genes encoding them. Now, research from Thomas Jefferson University’s Computational Medicine Center …

Mar 27 2026

Bristol-Myers Squibb Company: A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models

by Clinical Editor

No Comments

WASHINGTON, D.C. / ACCESS Newswire / March 27, 2026 / Originally published by the National Council for Mental Wellbeing The collaboration’s first initiative is a white paper demonstrating the value...